TABLE 7.
Ingredient | In vivo/In vitro | Model | Administration | Dose/Time | Treatment effect | Mechanism | Diseases | References |
---|---|---|---|---|---|---|---|---|
Salvia miltiorrhiza injection | In vivo | Femoral fracture in C57BL mice | Oral gavage | 0.5 mL/d for 14,16, 18, 22, 26, 34, 65 days | Accelerate calcium deposition | - | Delayed fracture union | Zhang (1984) |
Salvianolic acid B | In vivo | Rats tibia fracture model | Intraperitoneal injection | 40 mg/kg/d for 3 weeks | Increase ALP activity and the secretion of osteocalcin, and accelerate early fracture healing of the tibia in rats | - | Delayed fracture union | He and Shen (2014) |
Tanshinol | In vivo | Prednisone-induced delayed fracture union mouse model | Local injection | 5 mg/kg for 18 days | Accelerate callus mineralization rate and promote fracture callus formation and microstructure | - | Delayed fracture union | Liu et al. (2018) |
Tanshinol | In vivo; In vitro | Nonunion rabbits; ATDC5 | Loca injection | 5 mg/kg for 4 weeks; 0.1∼20 μmlo/L for 24, 48 and 72 h | Stimulate bone formation in the nonunion defect rabbit model, increase the expression of P-HDAC3, collagen II, Runx2, VEGFA, and OPN in vivo; accelerate endochondral ossification turnover | HDAC3-mediated endochondral ossification | Nonunion Healing | Zhou et al. (2020) |
Note: ALP, alkaline phosphatase; Runx2, Runt-related transcription factor 2; VEGFA, Vascular endothelial growth factor-A; OPN, Osteopontin; P-HDAC3, phosphorylated histone deacetylase; collagen II, Type 2 collagen.